A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction

Current Medical Research and Opinion

Volumn 29, Issue 6, 2013, Pages 695-706

  Rubio Aurioles, Eusebio ^a   Reyes, Luis Antonio ^b   Borregales, Leonardo ^c   Cairoli, Carlos ^d   Sorsaburu, Sebastian ^e  

^a A C AMSSAC Sexual Medicine Research   (Mexico)

^b Eli Lilly Mexico   (Mexico)

^c Centro Medico Docente La Trinidad   (Venezuela)

^d PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Adherence; Erectile dysfunction; Persistence; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

LODENAFIL; SILDENAFIL; TADALAFIL; VARDENAFIL;

ADULT; ARTICLE; BRAZIL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EDUCATIONAL STATUS; ERECTILE DYSFUNCTION; HUMAN; INTERNATIONAL INDEX ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEXICO; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; PARTNER RELATIONSHIP QUESTIONNAIRE; PERSISTENCE AND ADHERENCE QUESTIONNAIRE; PRESCRIPTION; PROSPECTIVE STUDY; SELF ESTEEM AND RELATIONSHIP QUESTIONNAIRE; SELF REPORT; TREATMENT DURATION; VENEZUELA;

CARBOLINES; CARBONATES; ERECTILE DYSFUNCTION; HUMANS; IMIDAZOLES; LATIN AMERICA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES; PURINES; PYRIMIDINES; QUESTIONNAIRES; SELF CONCEPT; SULFONES; TREATMENT OUTCOME; TRIAZINES;

EID: 84877295537     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.791262     Document Type: Article

References (33)

1. National Institutes of Health. Erectile Dysfunction. National Institutes of Health website: http://kidney.niddk.nih.gov/KUDiseases/pubs/ED/index.aspx. Accessed 21 August 2012
2. Torres LO, Ugarte y Romano F, Glina S. Erectile dysfunction epidemiology. Intl J Impot Res 2003;15(Suppl):S2-4
3. Chen KK, Jiann BP, Lin JS, et al. Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study. J Sex Med 2004;1:201-8
4. Rodrigues VL, Lledo GE, Rajmil O, et al. Preferencia de tadalafilo vs. sildenafilo en pacientes espanoles con disfuncion erectile: resultados procedentes de un studio multicentrico internacional. Actas Urol Esp 2006;30:67-79
5. Aytac IA, McKinley J, Krane RJ, et al. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Intl 1999;84:50-6
6. Rosen RC, Fisher WA, Eardley I, et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study I: prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20:607-17
7. Moreira Jr ED, Abdo CHN, Torres EB, et al. Prevalence and correlates of erectile dysfunction: results of the Brazilian study of sexual behavior. Urology 2001;58:583-8
8. Ugarte-Romano F, Barroso-Aguirre J. Prevalencia de disfuncion erectile en Mexico y factores de riesgo asociados. Rev Mex Urol 2001;61:63-76
9. Morillo LE, Diaz J, Estevez E, et al. Prevalence of erectile dysfunction in Colombia, Ecuador, and Venezuela: a population-based study (DENSA). Intl J Impot Res 2004;14(Suppl):S10-18
10. Nolazco C, Bellora O, Lopez M, et al. Prevalence of sexual dysfunctions in Argentina. Intl J Impot Res 2004;16:69-72
11. Fink HA, MacDonald R, Rutks IR, et al. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2002;162:1349-60
12. Hatzichristou D, Montorsi F, Buvat J, et al. The efficacy and safety of flexibledose vardenafil (Levitra) in a broad population of European men. Eur Urol 2004;45:634-41
13. Skoumal R, Chen J, Kula K, et al. Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. Eur Urol 2004;46:362-9
14. Von Keitz A, Rajfer J, Segal S, et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004;45:499-509
15. Rosen RC, Shabsigh R, Kuritzky L, et al. The efficacy of tadalafil in improving sexual satisfaction and overall satisfaction in men with mild, moderate, and severe erectile dysfunction: a retrospective pooled analysis of data from randomized, placebo-controlled clinical trials. Curr Med Res Opin 2005; 21:1701-9
16. Porst H, Rajfer J, Casabé A, et al. Long-term safety and efficacy of tadalafil 5mg dosed once daily in men with erectile dysfunction. J Sex Med 2008;5:2160-9
17. Rubio-Aurioles E, Casabe A, Torres LO, et al. Efficacy and safety of tadalafil in the treatment of Latin American men with erectile dysfunction: results of integrated analyses. J Sex Med 2008;5:1965-76
18. Rubio-Aurioles E, Glina S, Abdo CHN, et al. Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil: a geographical comparison from a single-arm, open-label study. J Sex Med 2009;6:2836-50
19. Ricardi U, Gontero P, Ciammella P, et al. Efficacy and safety of tadalafil 20 mg on demand versus tadalafil 5mg once-a-day in the treatment of postradiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial. J Sex Med 2010;7:2851-9
20. Glina S, Toscano I, Gomatzky C, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med 2009;6:553-7
21. Glina S, Fonseca GN, Bertero EB, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med 2010;7:1928-36
22. Roumeguere T, Verheyden B, Arver S, et al. Therapeutic response after first month of tadalafil treatment predicts 12 months treatment continuation in patients with erectile dysfunction: results from the DETECT study. J Sex Med 2008;5:1708-19
23. Mulhall JP, McLaughlin TP, Harnett JP, et al. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J Sex Med 2005;2:848-55
24. Hatzichristou D, Moysidis K, Apostolidis A, et al. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol 2005;47:518-23
25. Gruenwald I, Shenfeld O, Chen J, et al. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 2006;50:134-40
26. Hatzimouratidis K, Moysidis K, Bekos A, et al. Treatment strategy for 'nonresponders' to tadalafil and vardenafil: a real-life-study. Eur Urol 2006;50:126-33
27. Klotz T, Mathers M, Klotz R, et al. Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra) Intl J Impot Res 2005;17:2-4
28. Jiann BP, Yu C-C, Su C-C, et al. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Intl J Impot Res 2006;18:146-9
29. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30
30. Althof SE, Corty EW, Levine SB, et al. EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999;53:793-9
31. Cappelleri JC, Althof SE, Siegel RL, et al. Development and validation of the Self-Esteem and Relationship (SEAR) questionnaire in erectile dysfunction. Intl J Impot Res 2004;16:30-8
32. Mulhall JP, Goldstein I, Bushmakin AG, et al. Validation of the erection hardness score. J Sex Med 2007;4:1626-34
33. Leemis LM, Trivedi KS. A comparison of approximate interval estimators for the Bernoulli parameter. Amer Statist 1996;50:63-8